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ABSTRACT
Introduction Chronic lung disease of prematurity (CLD), 
also known as bronchopulmonary dysplasia (BPD), is a 
cause of significant respiratory morbidity in childhood 
and beyond. Coupled with lung immaturity, infections 
(especially by Ureaplasma spp) are implicated in the 
pathogenesis of CLD through promotion of pulmonary 
inflammation. Azithromycin, which is a highly effective 
against Ureaplasma spp also has potent anti- inflammatory 
properties. Thus, azithromycin therapy may improve 
respiratory outcomes by targeting infective and 
inflammatory pathways. Previous trials using macrolides 
have not been sufficiently powered to definitively assess 
CLD rates. To address this, the azithromycin therapy for 
chronic lung disease of prematurity (AZTEC) trial aims 
to determine if a 10- day early course of intravenous 
azithromycin improves rates of survival without CLD when 
compared with placebo with an appropriately powered 
study.
Methods and analysis 796 infants born at less than 30 
weeks’ gestational age who require at least 2 hours of 
continuous respiratory support within the first 72 hours 
following birth are being enrolled by neonatal units in 
the UK. They are being randomised to receive a double- 
blind, once daily dose of intravenous azithromycin (20 
mg/kg for 3 days, followed by 10 mg/kg for a further 7 
days), or placebo. CLD is being assessed at 36 weeks’ 
PMA. Whether colonisation with Ureaplasma spp 
prior to randomisation modifies the treatment effect 
of azithromycin compared with placebo will also be 
investigated. Secondary outcomes include necrotising 
enterocolitis, intraventricular/cerebral haemorrhage, 
retinopathy of prematurity and nosocomial infections, 
development of antibiotic resistance and adverse reactions 
will be monitored.
Ethics and dissemination Ethics permission has been 
granted by Wales Research Ethics Committee 2 (Ref 18/
WA/0199), and regulatory permission by the Medicines 
and Healthcare Products Regulatory Agency (Clinical Trials 
Authorisation reference 21323/0050/001–0001). The study 
is registered on ISRCTN (ISRCTN11650227). The study is 
overseen by an independent Data Monitoring Committee 
and an independent Trial Steering Committee. We shall 
disseminate our findings via national and international 
peer- reviewed journals, and conferences. A summary of 
the findings will also be posted on the trial website.
INTRODUCTION
Chronic lung disease of prematurity (CLD), 
also known as bronchopulmonary dysplasia 
(BPD), is a major cause of neonatal death 
in infants born prematurely. It is clear that 
survivors of CLD have adverse respiratory 
outcomes in childhood and beyond.1–3
Despite the advances in neonatal care, rates 
of CLD have not markedly changed. This is 
largely because of the survival of the most 
immature infants born at the limits viability 
Strengths and limitations of this study
 ► This is a randomised, double- blind, placebo- 
controlled trial assessing an important outcome, and 
using an intervention which could be readily imple-
mented in clinical practice.
 ► If the assumptions underlying the sample size cal-
culation are valid, this study will be appropriately 
powered for the primary outcome.
 ► The study will also help address the role of pulmo-
nary Ureaplasma spp colonisation in the develop-
ment of chronic lung disease of prematurity.
 ► Universal administration of azithromycin may alter 
antibiotic resistance patterns, which are also being 
investigated in this study.
 ► Further work will be required to investigate the 
mechanistic action of azithromycin, including on the 
lung and gut microbiota.
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(22 to 23 weeks’ gestation), which means that the propor-
tion of preterm infants born at 28 weeks or less of gestation 
has increased over the last 30 years.4 Consequently, the 
etiological definition of CLD was modified to represent 
the structural immaturity of the lungs which are in the 
canalicular/saccular stages of development.5 6 The patho-
physiology is complex and results from continual lung 
injury caused by inflammatory processes coupled with 
repair/remodelling and resultant fibrosis.7 In contrast, 
the historical picture of CLD was largely characterised by 
parenchymal tissue damage caused by volutrauma, baro-
trauma and by high levels of oxygen required to sustain 
life.8
Infections, both antenatal (eg, chorioamnionitis) and 
nosocomial, contribute to a cytokine- mediated inflam-
matory cascade which peaks between 7 to 10 days of 
life.9 10 Ureaplasma spp (class Mollicutes) are the smallest 
free living organisms and have long been implicated in 
the pathogenesis of CLD.11 These commensal bacteria 
form part of the normal vaginal bacteria microbiota, and 
thus are readily transmitted to the uterus via the cervix 
or acquired during vaginal delivery. Lacking a cell wall, 
they are readily transferred to the lung where they colo-
nise the respiratory mucosa and directly or, in conjunc-
tion with aforementioned iatrogenic factors, indirectly 
promote inflammation largely through recruitment of 
neutrophils to the lung. Our recent systematic review and 
meta- analysis reported that Ureaplasma spp colonisation 
was strongly associated with diagnosis of CLD at 36 weeks’ 
post- menstrual age (PMA; OR 2.22; 95% CI 1.42 to 3.47) 
which was largely independent of gestational age when 
investigated with meta- regression.12
Current treatments for the prevention of CLD are 
largely supportive and include optimising use of early 
non- invasive respiratory support and preventing infec-
tions. Use of systemic corticosteroids is considered in 
cases where the infant is unable to be weaned from inva-
sive ventilation. However, although early low- dose regi-
mens may be beneficial in a high- risk subpopulation, it 
is well- established that higher doses of corticosteroids are 
associated with adverse neurodevelopmental outcomes, 
including cerebral palsy.13
Due to the potential risks associated with use of corti-
costeroids, other treatments, or ideally preventive strate-
gies, with improved safety profiles are urgently required 
for CLD. An interest in macrolide antibiotics, and the 
potential for improving lung outcomes via eradication of 
Ureaplasma, was established in the 1990s. However, early 
trials of erythromycin were underpowered and did not 
reduce the incidence or severity of CLD.14 A study trialling 
clarithromycin treatment for 10 days reported a reduc-
tion in CLD (2.9% vs 36%) when compared with placebo 
but importantly only initiated delayed randomised 
therapy if the infant was culture- positive for Ureaplasma.15 
More contemporary data exists with azithromycin, which 
is an important adjunct therapy for numerous respira-
tory conditions, including cystic fibrosis and chronic 
obstructive pulmonary disease (COPD). Consistent with 
other macrolides, azithromycin inhibits bacterial protein 
synthesis through blinding to the 50S bacterial ribosomal 
subunit.16 Moreover, azithromycin is attractive as it also 
uniquely exhibits well- characterised immunomodulatory 
effects through suppression of nuclear factor- kappaB, 
decreasing neutrophilic pulmonary inflammation by 
limiting the production of pro- inflammatory cytokines 
such as interleukin (IL)-6 and IL-8.17 Furthermore, since 
azithromycin is concentrated in leukocytes, it may be 
actively transported and released at the site of infection.18
Several proof of concept and dose- finding studies have 
already been completed. The meta- analysis by Nair and 
colleagues showed that azithromycin treatment is asso-
ciated with a 14% reduction in the combined outcome 
of CLD/death when compared with placebo.19 Dose- 
finding work in respect of Ureaplasma spp eradication has 
been undertaken in a series of studies by Viscardi and 
colleagues.20–22 Importantly, all previous studies did not 
note any serious adverse reactions to azithromycin and 
add to the existing safety information.23 Antimicrobial 
resistance among Ureaplasma remains low.24
Given the Nair meta- analyses and lack of adequately 
powered studies, and given the reported association of 
presence of pulmonary inflammation and Ureaplasma 
with development of CLD, there is a compelling case for 
a definitive, adequately powered study to investigate the 
effectiveness of azithromycin on reducing rates of CLD 
in preterm infants. The azithromycin therapy for chronic 
lung disease of prematurity (AZTEC) trial is determining 
if a 10- day course of intravenous azithromycin improves 
rates of survival without CLD at 36 weeks’ PMA when 
compared with placebo.
METHODS AND ANALYSIS
Primary objective
The primary objective of the AZTEC trial is to assess 
the effectiveness of a 10- day course of azithromycin on 
improving survival without physiologically- defined CLD 
in infants born at <30 weeks’ gestational age.
Design
AZTEC is a double- blind, randomised, placebo- controlled 
trial. The total samples size is 796 preterm- born infants; 
each are randomised individually (including infants from 
a multiple birth). Follow- up is undertaken at 36 weeks’ 
PMA to assess CLD status at 36 weeks’ PMA, with final 
follow- up a discharge from hospital.
Setting
Infants are being enrolled from UK tertiary neonatal 
units, which are designated Level III (regional neonatal 
intensive care units), and followed up at their local 
hospital if transferred. Infants are identified by the study 
team on admission and screened against the inclusion/
exclusion criteria.
Inclusion criteria
1. Gestational age ≤29 weeks+6 days (including infants 
born as one of a multiple birth)
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2. Infants who receive respiratory support for at least 2 
continuous hours’ duration during the first 72 hours 
of life (intubated, or by non- invasive mechanical ven-
tilation, including continuous positive airway pressure 
and high- flow nasal cannula, or a combination there-
of).
3. Presence of an indwelling intravenous line for drug 
administration.
4. Written informed parental/guardian consent within 
72 hours of birth.
5. Anticipating administration of first dose within 72 
hours of birth at the latest (optimally targeting within 
24 hours after birth for inborn and 48 hours for out-
born infants).
6. Reasonable expectancy to complete 10 days of trial 
treatment while resident at the recruiting site.
7. Inborn, or born at site within the recruiting site’s neo-
natal network where follow- up will be possible.
8. In the opinion of the local principal investigator (PI), 
reasonable prospect of survival past the first 72 hours 
of life.
Exclusion criteria
1. Exposure to another systemic macrolide antibiotic 
(not maternal)
2. Presence of major surgical or congenital abnormalities 
(not including patent ductus arteriosus or patent fora-
men ovale)
3. Contraindication of azithromycin as specified in the 
summary of product characteristics (SPC)
4. Participation in other interventional trial that pre-
cludes participation in AZTEC
Trial intervention
The investigational medicinal product (IMP) is manufac-
tured and QP released by Saint Mary’s Pharmaceutical 
Unit (SMPU), Cardiff, UK (MIA(IMP)35929).
The dosing schedule is 20 mg/kg (10 mL/kg) azithro-
mycin for 3 days, followed by 10 mg/kg (5 mL/kg) for 
7 days or placebo (10 days total). All doses are given via 
intravenous infusion (central or peripheral line) over a 
period of at least 1 hour. Azithromycin is most likely to 
have an effect when administered early to establish a suffi-
cient concentration to eliminate Ureaplasma; a 20 mg/kg 
dose for 3 days has recently been shown to be highly effec-
tive.22 Treatment for a further 7 days is justified to treat 
the rise in pulmonary inflammation which peaks between 
7 and 10 days after birth.9 25 Sites have therefore been 
asked to target initiation of trial treatment at the earliest 
opportunity (and within 72 hours after birth at the latest).
Blinding
IMP is supplied as a patient pack of 12 blinded vials. 
The vial blinding method uses a custom cardboard 
carton sourced by SMPU, as used previously in a similar 
trial design.26 Labelling was performed by SMPU as per 
a randomisation list provided by the Centre for Trials 
Research (CTR), Cardiff University.
Active arm
The active arm comprises of commercially- available 
500 mg vials of azithromycin powder for solution for 
infusion (Aspire Pharma Ltd). As per the summary of 
product characteristics (https://www. medicines. org. uk/ 
emc/ product/ 1276/ smpc), 4.8 mL sterile water is used 
to reconstitute the powder to obtain a clear, colourless 
solution of 100 mg/mL. The administration concentra-
tion of 2 mg/mL is obtained by withdrawing 1 mL of solu-
tion from the vial and adding to 50 mL of an acceptable 
diluent.
Control arm
The placebo arm initially comprised of an empty, sterile 
vial manufactured to the same specification as the active 
product (released under GMP standards) and provided 
to SMPU by Aspire Pharma Ltd for blinding and pack-
aging. The same preparation steps are followed as per the 
active arm to produce a solution matching in appearance 
to the active arm.
OUTCOMES
Primary outcome
The primary outcome is a combined outcome of CLD 
(moderate- severe) and mortality at 36 weeks’ PMA (or 
discharge, if sooner). The definition of CLD severity is 
based on consensus criteria,27 table 1.
Infants meeting the initial diagnosis of moderate CLD 
will undergo a physiological test to confirm their oxygen 
requirement (figure 1). This physiological definition, 
initially developed by Quine and colleagues,28 has been 
widely used in clinical trials of neonatal lung disease.29
Secondary outcomes will include
1. Mortality rate by 36 weeks PMA.
2. CLD severity by 36 weeks of age or discharge.
3. Number of days of respiratory support/oxygen depen-
dency.
4. Development of complications of prematurity.
a. Nosocomial infection.
Table 1 Severity- based criteria for diagnosis of CLD at 36 
weeks post- menstrual age
Received respiratory support and/or supplementary oxygen 
for more than 28 days, cumulatively, and the following:
Mild CLD  ► Breathing room air
Moderate CLD  ► Require <30% oxygen (or low flow 
0.01 to 1.0 L/min), not receiving any 
respiratory support
Severe CLD  ► Require ≥30% oxygen (or low flow 
≥1.1 L/min), still receiving respiratory 
support (ventilation, CPAP, high- flow 
oxygen)
CLD, chronic lung disease of prematurity; CPAP, continuous 
positive airway pressure.
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b. Severe intraventricular haemorrhage (grade III/
IV).
c. Necrotising enterocolitis (Bell stage II and above).
d. Treatment for retinopathy of prematurity.
e. Treatment for patent ductus arteriosus.
f. Liver and renal function.
5. Serious adverse events/reactions.
6. Resistance to macrolides among microbes isolated 
from stool samples.
Trial procedures
Site selection and training
Site selection is based on receipt of an expression of 
interest via the National Institute for Health Research 
(NIHR) networks and personal contact directly with UK 
Level III neonatal units. A registration questionnaire 
captures key information about the site, trial team and 
any concerns around delivery of the protocol in the 
context of routine practice. Where feasible, a preliminary 
visit is made by the Trial Manager to present the study 
background and protocol. The Trial Management Group 
approved the centres selected to participate.
Formal initiation visits are held at each site to train 
the local trial team in trial- specific procedures. This is 
supplemented with comprehensive guidance documents 
for discrete elements of the study. Specific training in 
preparation and administration of the IMP is cascaded 
down by delegated members of the local study team to 
cot- side nurses; this includes a video produced by JL with 
support from neonatal nurses and the medical illustration 
department at Cardiff and Vale University Health Board 
(https:// youtu. be/ Xto6n5qFuYQ). The local clinical 
trials pharmacy team are also provided with trial- specific 
training in IMP storage, accountability and reconciliation 
procedures during the initiation process. All local study 
teams have undertaken Good Clinical Practice training 
commensurate with their roles and responsibilities.
Figure 1 Flow diagram for assessment of CLD severity in the AZTEC trial. Modified from the original https://www.npeu.ox.ac.
uk/downloads/files/baby-oscar/protocol/Baby-OSCAR_Protocol_v6_171116.pdf. AZTEC, azithromycin therapy for chronic lung 
disease of prematurity; CLD, chronic lung disease of prematurity; FIO2, fraction of inspired oxygen.
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Participant recruitment
The trial design is summarised in figure 2. Recruitment 
is anticipated to take 30 months, with 25 sites partici-
pating (an average of 1.5 infants per site, per month over 
the course of recruitment). Progress of the trial can be 
followed at www. aztec- trial. uk
Screening and consent
It is anticipated that all infants who meet the gestational 
age criteria for the trial (ie, born <30 weeks’ gestational 
age) are registered on the anonymised screening log. 
Reasons for exclusion, and reasons for not randomising 
otherwise eligible infants (eg, declined consent) are 
being recorded.
A member of the local site team identifies potential 
eligible preterm babies antenatally with mothers with 
threatened preterm labour or babies admitted to the 
neonatal unit and the parent(s) receive a verbal descrip-
tion of the trial. Should the parent(s) express an interest, 
the ethically- approved information sheet and consent 
form are provided (online supplemental file). Eligibility 
is confirmed by a medically qualified member of the trial 
team. Parents are given sufficient time to read the infor-
mation and to ask questions during a further consultation 
with the study team. If the parents are willing to partic-
ipate, they are asked to sign the consent form which is 
countersigned by the PI or a delegated member of the 
study team who engaged the parents in the informed 
consent discussion. Consent for use of samples in ancil-
lary studies, and for future follow- up contact are optional. 
The right to withdraw from the study at any time without 
Figure 2 Flow diagram for AZTEC study procedures and follow- up. AZTEC, azithromycin therapy for chronic lung disease of 
prematurity; ETA, endotracheal aspirates; NPA, nasopharyngeal aspirates.
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any affecting their baby’s clinical care will be clearly 
communicated.
Randomisation
Randomisation to the intervention is performed following 
confirmation of eligibility and completion of the informed 
consent process. The randomisation list prepared by an 
independent CTR statistician uses a 1:1 allocation ratio 
with fixed block length. Allocation to azithromycin or 
placebo is blinded such that the allocation will not be 
known to clinicians, the baby’s family or the trial outcome 
assessors. The list is uploaded to a validated, user- tested, 
web- based system (Sortition, Oxford University Inno-
vation Ltd). Randomisation is performed by a member 
of the local study team using a unique username and 
password. The system performs treatment allocation by 
issuing a random four- digit IMP pack ID (matching the 
IMP supplied to each site), and also a participant ID in 
a standardised format. A member of the site study team 
retrieves the appropriate pack of IMP from the storage 
location and ensures this is appropriately prescribed on 
the infant’s prescription chart. Unblinding, if required, 
may also be performed by the site PI (or designee) using 
the web- based system.
Data collection and sampling
Clinical assessments
Following documentation of eligibility, the focus of the 
baseline data collection is on maternal history and ante-
natal information, and details around the infant’s birth.
IMP administration, sample collection, use of intrave-
nous antibiotics and details of any positive blood/cere-
brospinal fluid cultures are recorded on a daily basis until 
the infant is 21 days post randomisation. Liver and kidney 
function will be monitored through collection of stan-
dard laboratory values. Should the infant be transferred 
from the AZTEC recruiting site to another hospital for 
continuation of care, the receiving centre continues with 
follow- up assessments to support collection of primary 
and secondary outcomes.
Infants remain in follow- up for safety and outcome 
purposes until 36 weeks’ PMA, or are discharged home 
sooner (the last time point for recording new adverse 
reactions).
Data collection
All data are recorded on the trial electronic Case Report 
Form. Accumulating data are regularly monitored and 
queries raised with sites should values be missing or 
otherwise erroneous (eg, validation against pre- specified 
ranges for laboratory values).
Sampling
Sites are collecting serial respiratory secretions and stool 
samples in a pragmatic, opportunistic manner around 
nominal time points of baseline, day 5, day 10 and days 14 
to 21 post- randomisation. These procedures are timed to 
mirror standard care to minimise disturbing trial infants, 
where possible. Endotracheal aspirates are obtained if 
the infant is intubated, and nasopharyngeal aspirates 
are collected if they are not. Stool samples are collected 
opportunistically whenever the infants open their bowels. 
All samples are refrigerated until shipment at the earliest 
opportunity overnight to the central laboratory where 
they are processed according to a standardised procedure 
and stored at −80°C pending analysis. A schematic of the 
sampling plan is show in figure 3.
Analysis
Sample size
Relevant interventional studies to prevent development of 
CLD as an outcome (including studies using macrolides) 
in preterm infants were reviewed. In general, national and 
international studies consistently show rates of survival 
without CLD of 50% to 60% (those with lower rates are 
due to highly selected groups of sicker participants) for 
Figure 3 AZTEC biological sampling plan* day 4 to 6 is acceptable for the day 5 samples. Day 8 to 12 is acceptable for the 
day 10 samples. Day 14 to 21—one sample of each type during this period. AZTEC, azithromycin therapy for chronic lung 
disease of prematurity; CLD, chronic lung disease of prematurity; ETA, endotracheal aspirates; NPA, nasopharyngeal aspirates.
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studies with similar inclusion criteria to AZTEC. Thus, 
adopting a conservative approach using 50% survival 
without developing CLD is reasonable. Similarly, the abso-
lute differences in effect size ranges from 10% to 20% in 
most studies. The study is powered to an improvement of 
12% (50% to 62%) in survival without CLD with a power 
of 0.90 and significance level of 5% requiring recruitment 
of 796 subjects which is highly feasible as shown by several 
similar UK studies in this population. Since the primary 
outcome will involve formal assessment with an oxygen 
challenge test in both tertiary units and in step- down 
units, a dropout rate of 10% has been estimated.
Statistical analysis
We are conducting an internal pilot involving the first 
five sites to be activated, and for a period of 12 months 
(9 months of recruitment and 3 months of follow- up). A 
pilot report will be produced detailing information on 
recruitment rate, consent rates, treatment compliance 
and primary outcome completeness. The report will be 
presented to the funder and the AZTEC independent 
committees to help inform any adaptations necessary to 
facilitate moving forward with the main trial. No formal 
interim analysis is planned.
The trial will be analysed and reported using the ‘Consol-
idated Standards of Reporting Trials’ (CONSORT)30 and 
the International Conference on Harmonization (ICH) 
E9 guidelines.31 A separate and full statistical analysis 
plan has been developed prior to database lock. The 
analysis plan will be reviewed by the AZTEC independent 
committees.
The principle of intention- to- treat will be applied as far 
as practically possible, including all participants in the 
primary analysis in the group to which they were randomly 
allocated. All analyses will use a 5% level of statistical signif-
icance and 95% CI will be presented throughout. The 
primary outcome will be analysed using multilevel logistic 
regression, within a multiple imputation framework. The 
analysis will adjust for covariates balanced at randomisa-
tion and account for clustering of both multiple births 
and participants within centres. The imputation model 
will use the treatment arm and gestational age variables, 
as well as whether or not the participant was transferred 
from their recruiting site prior to the primary outcome 
assessment. Furthermore, a series of sensitivity analyses, 
within the multiple imputation framework, will be used 
to assess the robustness of conclusions.
The presence of multiple births within the same preg-
nancy will be explored by including this as an additional 
level in the model, and this will be used as the primary 
analytical approach should the model converge. Dichot-
omous secondary outcomes will be analysed using the 
same approach. Number of days of respiratory support 
will be analysed as a time to event outcome allowing for 
competing risk of death. These models will also attempt 
to account for any clustering effects of multiple births 
within the same mother. Statistical tests will not be used 
on safety and tolerability outcomes. These outcomes will 
use descriptive statistics only.
To explore the extent to which there may be a differ-
ential treatment effect by presence of Ureaplasma spp, the 
model fitted for the primary analysis will be extended by 
including a main and treatment group interaction term 
for Ureaplasma spp colonisation at baseline. Since patterns 
of Ureaplasma colonisation may vary,22 32 the approach 
to this analysis may be modified in respect of emerging 
trends identified the placebo group samples. The final 
analytical approach will be agreed prior to database lock. 
Estimates from the statistical models (main effects and 
interaction terms) will be presented alongside 95% CI 
and p values.
There are no formal stopping rules but the safety 
data will be regularly reviewed by the Trial Management 
Group, and at least annually by the independent Data 
Monitoring Committee.
Microbiology
Respiratory samples are being processed via centrifu-
gation to separate the supernatant and obtain a cell 
pellet from which DNA will be extracted. Identification 
of Ureaplasma urealyticum, Ureaplasma parvum and Myco-
plasma hominis is being performed using multiplex quan-
titative PCR (qPCR) assay as previously described.33 34 All 
DNA extractions and qPCR assays are being performed 
in collaboration with Central Biotechnology Services 
(Cardiff University, UK) according to standard operating 
procedures and GCP to minimise contamination.
Stool samples are being cultured aerobically and non- 
aerobically, and in the presence and absence of azith-
romycin to assess baseline and new development of 
azithromycin- resistant organisms.
DISCUSSION
As the survival of preterm infants increases, decreasing 
morbidity associated with prematurity, including CLD, is 
becoming increasingly important. AZTEC is an example 
of evaluating drug development35 in infants as a large, 
pragmatic and adequately powered trial of a macrolide 
antibiotic to prevent development of CLD with wide-
spread support by the neonatal community.36 37 The 
importance of improving outcomes for preterm infants 
at risk of developing CLD is highlighted by the poten-
tial impacts on later pulmonary function, especially the 
prospect of early decline in lung function and early- onset 
COPD.38 Moreover, the evidence base to treat graduates 
of the neonatal unit when they present with symptoms 
in childhood is poor,39 largely because the mechanisms 
of prematurity- associated respiratory morbidity remain 
poorly understood.40
Whether modification of pulmonary inflammation and 
treatment of Ureaplasma infection would reduce rates of 
CLD has been debated for three decades. Use of postnatal 
corticosteroids is associated with long- term adverse effects; 
however, the safety profile of azithromycin is superior 
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and is unlikely to affect neurological outcomes. Plans to 
follow- up neurodevelopment and respiratory outcomes 
at 1 and 2 years of age are in place. This study includes 
ascertainment of whether each infant is colonised with 
Ureaplasma spp and randomisation of treatment to azith-
romycin or placebo. Given the time lag between rando-
misation and the results of tests for Ureaplasma spp, the 
randomisation will not be balanced for Ureaplasma status. 
Nevertheless, this study design will allow an assessment 
of the causative role of Ureaplasma in the development of 
CLD.
If effectiveness of azithromycin therapy is demon-
strated, integration into standard care would be relatively 
straightforward since the majority of candidates for treat-
ment would have intravenous access for 7 to 10 days. Estab-
lishing whether azithromycin alters antibiotic resistance 
patterns will provide important information to the clini-
cian who may have concerns around adding an adjunct 
treatment to a wide array of antimicrobials already given 
to this vulnerable group of patients. Although AZTEC 
will not specifically address mechanistic actions of azith-
romycin, including its effect on the lung and gut micro-
biota, samples will be banked to permit such work in the 
near future using established25 and novel methodologies 
such as metagenomics.41
In summary, the AZTEC trial is addressing an 
important therapeutic need in an area where treatment 
based on high- quality evidence is severely lacking. Should 
antimicrobial resistance not be affected, azithromycin 
therapy should be appealing to clinicians due to the anti- 
inflammatory properties and proven ability to eradicate 
Ureaplasma. Treatment may yield fewer intensive care days 
and fewer discharges on home oxygen, resulting in consid-
erable reduction in costs to the National Health Service 
(NHS), as well as decreasing the significant burden on 
parents. On the other hand, should the treatment not be 
clinically effective, the neonatal research community can 
turn their attention to alternative options for combating 
CLD. Identification of an effective treatment to prevent 
CLD would be of exceptional value to the NHS, infants 
and their families.
ETHICS AND DISSEMINATION
The current version of the AZTEC protocol is 3.0, 
dated 20 June 2020. Ethics permission has been granted 
by the Wales Research Ethics Committee 2 (Ref 18/
WA/0199), and regulatory permission by the Medicines 
and Healthcare Products Regulatory Agency (CTA refer-
ence 21323/0050/001–0001). NHS permission has been 
granted by the Health Research Authority (HRA) and 
capacity and capability confirmed by each individual NHS 
organisation. The study is registered on EudraCT (2018-
001109-99), ISRCTN (ISRCTN11650227) and on the 
NIHR portfolio (CPMS 39385). Cardiff University is the 
Sponsor ( resgov@ cardiff. ac. uk), and were not involved 
in the preparation of this manuscript or the decision to 
submit. Personal data is held with the explicit consent 
of participants, independently of study data. The CTR 
has policies and procedures relating to data requests: 
https://www. cardiff. ac. uk/ centre- for- trials- research/ 
about- us/ data- requests. We shall disseminate our findings 
via national and international peer- reviewed journals, 
and conferences. A summary of the findings will also be 
posted on the trial website.
Oversight of the study is being performed by an inde-
pendent Data Monitoring Committee (comprising two 
expert neonatologists, and an expert statistician) and 
an independent Trial Steering Committee (comprising 
two expert neonatologists, an expert statistician and a lay 
representative). Appointments to these committees were 
made with approval of the NIHR HRA and meeting a 
being held at least annually.
Patient and public involvement
Parental input was obtained during the grant application 
on the design and conduct of the study. Parent represen-
tatives also reviewed public- facing information (eg, infor-
mation sheets and consent form) and are members of the 
Trial Management Group. An independent parent repre-
sentative is a member of the Trial Steering Committee.
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